Smaller Vaccine Companies Gain Ground
The COVID-19 pandemic will likely cause long-lasting changes for the vaccine industry. For years, four main publicly traded companies dominated the industry, selling billions of dollars worth of vaccines each year. Those companies were Pfizer (PFE), Merck (MRK), GlaxoSmithKline (GSK), and Sanofi (SNY).
As the race to create and then distribute a COVID-19 vaccine unfolded, other companies like Moderna (MRNA) and Novavax (NVAX) gained power in the space. These companies have been more nimble than some of their larger counterparts. They were able to ship their vaccine doses directly to government warehouses and did not have to hire large sales forces.
How the Vaccine Market Differs From Other Healthcare Markets
The Biden administration said that the US will have 600 million total doses of the Moderna and Pfizer vaccines by July, which will be enough to immunize most of the population. Investors are now beginning to look ahead and think about what distribution of vaccines for COVID-19 and other illnesses will look like after this milestone is achieved.
The market for vaccines is different than the market for other drugs because it is not generally driven by physician or consumer choices. Patients usually do not have a choice about which vaccine they receive for the flu or other illnesses. Vaccine companies make money from large contracts and compete on price. They do not typically compete for attention from individuals.
New Technologies for Vaccine Development
The tools available to vaccine developers have also been changed as a result of the pandemic. Companies have found new ways to employ messenger RNA technology, viral vector technology, and other methods of vaccine development. These achievements could accelerate the process of making new vaccines in the future.
There are still hurdles to overcome in the process of distributing COVID-19 vaccines around the world. But there is light at the end of the tunnel, and the advancements that have taken place during the pandemic will have far-reaching effects on vaccine development in the future.
Please understand that this information provided is general in nature and shouldn’t be construed as a recommendation or solicitation of any products offered by SoFi’s affiliates and subsidiaries. In addition, this information is by no means meant to provide investment or financial advice, nor is it intended to serve as the basis for any investment decision or recommendation to buy or sell any asset. Keep in mind that investing involves risk, and past performance of an asset never guarantees future results or returns. It’s important for investors to consider their specific financial needs, goals, and risk profile before making an investment decision.
The information and analysis provided through hyperlinks to third party websites, while believed to be accurate, cannot be guaranteed by SoFi. These links are provided for informational purposes and should not be viewed as an endorsement. No brands or products mentioned are affiliated with SoFi, nor do they endorse or sponsor this content.
Communication of SoFi Wealth LLC an SEC Registered Investment Advisor
SoFi isn’t recommending and is not affiliated with the brands or companies displayed. Brands displayed neither endorse or sponsor this article. Third party trademarks and service marks referenced are property of their respective owners.